Smart drug targets two cancer weaknesses at once
NCT ID NCT07686445
First seen Jul 07, 2026 · Last updated Jul 15, 2026 · Updated 4 times
Summary
This trial tests a new drug called AN4035 in people with advanced solid tumors that have RAS mutations and high levels of the CEACAM5 protein. The drug is designed to seek out cancer cells carrying CEACAM5 and deliver a payload that blocks RAS, a key driver of cancer growth. The study aims to find safe doses and see if the drug can slow or shrink tumors, either alone or combined with another cancer drug (cetuximab).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AN4035 (a drug that targets CEACAM5 on cancer cells and delivers a RAS inhibitor payload)
- What this could lead to
- If successful, this could lead to a new treatment option for people with hard-to-treat cancers that have RAS mutations and high CEACAM5 levels.
- What could go wrong
- This is an early-phase trial, so the drug may not be safe or effective. Side effects could be significant, and the approach may not work for all tumor types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CEACAM5 are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Linear
Perth, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Scientia Clinical Research
Sydney, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill targets Hard-to-Treat cancers with KRAS mutation
- New drug combo targets Hard-to-Treat cancers with RAS mutations
- New drug RSC-1255 takes on Hard-to-Treat cancers
- New pill targets Hard-to-Treat cancers with RAS gene flaw
- Massive study aims to unlock secrets of rare genetic disorders
- New MEK inhibitor PAS-004 enters human trials for Hard-to-Treat cancers